High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B

Journal of Medical Virology

Volumn 82, Issue 9, 2010, Pages 1481-1488

  Mendes Correa, M C ^a   Pinho, J R R ^b,c   Locarnini, S ^d   Yuen, L ^d   Sitnik, R ^b   Santana, R A F ^b   Gomes Gouvea M S ^c   Leite, O M ^a   Martins, L G ^e   Silva, M H ^e   Gianini, R J ^c   Uip, D E ^a  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^e Clinica Municipal de Especialidades Médicas   (Brazil)

Author keywords

Hepatitis B; HIV; Lamivudine; Resistance mutations; Tenofovir

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TENOFOVIR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; DNA SEQUENCE; DRUG EXPOSURE; ENVELOPE GENE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROMOTER REGION; UNINDEXED SEQUENCE; VIREMIA; VIRUS GENE; VIRUS GENOME; VIRUS LOAD; VIRUS MUTATION;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; COMORBIDITY; CROSS-SECTIONAL STUDIES; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MUTATION; PHOSPHONIC ACIDS; VIRAL CORE PROTEINS; VIRAL LOAD; VIRAL PROTEINS;

HEPATITIS B VIRUS;

EID: 77956580657     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21845     Document Type: Article

References (40)

1. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palù G, Reiss P, Thiebaut R, Weiland O, Yazdanpanah Y, Zeuzem S. ECC Jury. 2005. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 42:615-624.
2. Alencar RS, Gomes MM, Sitnik R, Pinho JR, Malta FM, Mello IM, Mello ES, Bacchella T, Machado MC, Alves VA, Carrilho FJ. 2008. Low occurrence of occult hepatitis B virus infection and high frequency of hepatitis C virus genotype 3 in hepatocellular carcinoma in Brazil. Braz J Med Biol Res 41:235-240.
3. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T. 1999. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30:1302-1306. (Pubitemid 29510871)
4. Bodsworth N, Donovan B, Nightingale BN. 1989. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: A study of 150 homosexual men. J Infect Dis 160:577-582.
5. Bonacini M, Govindarajan S, Redeker AG. 1991. Human immunodeficiency virus infection does not alter serum transaminases and hepatitis B virus (HBV) DNA in homosexual patients with chronic HBV infection. Am J Gastroenterol 86:570-573.
6. Bottecchia M, Souto FJ, O KM, Amendola M, Brandão CE, Niel C, Gomes SA. 2008. Hepatitis B virus genotypes and resistance mutations in patients under longterm lamivudine therapy: Characterization of genotype G in Brazil. BMC Microbiol 8:11.
7. Braga WS, da Costa Castilho M, dos Santos IC, Moura MA, Segurado AC. 2006. Low prevalence of hepatitis B virus, hepatitis D virus and hepatitis C among patients with human immunodeficiency virus. Rev Soc Bras Med Trop 39:519-522.
8. Cao GW. 2009. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol 15:5761-5769.
9. CassinoL, Laufer N, Salomon H, Campos R, Quarleri J. 2009. Hepatitis B precore/core promoter mutations in isolates from HBV-monoinfected and HBV-HIV coinfected patients: A 3-yr prospective study. J Clin Virol 46:354-359.
10. Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, Mijch A, Locarnini S, Sasadeusz J. 2003. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV coinfected individuals. AIDS 17:1649-1657.
11. Delaney WE IV, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S. 2003. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77:11833-11841.
12. Devesa M, Loureiro CL, Rivas Y, Monsalve F, Cardona N, Duarte MC, Poblete F, Gutierrez MF, Botto C, Pujol FH. 2008. Subgenotype diversity of hepatitis B virus American genotype F in Amerindians from Venezuela and the general population of Colombia. J Med Virol 80:20-26.
13. Fang ZL, Sabin CA, Dong BQ, Ge LY, Wei SC, Chen QY, Fang KX, Yang JY, Wang XY, Harrison TJ. 2008. HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: A prospective study. Am J Gastroenterol 103:2254-2262.
14. Gomes-Gouvêa MS, Soares MC, Bensabath G, de Carvalho-Mello IM, Brito EM, Souza OS, Queiroz AT, Carrilho FJ, Pinho JR. 2009. Hepatitis B and Delta virus genotypes in outbreaks of fulminant hepatitis (Labrea black fever) in the Western Brazilian Amazon region. J Gen Virol 90:2638-2643.
15. Greco DB, Simão M. 2007. Brazilian policy of universal access to AIDS treatment: Sustainability challenges and perspectives. AIDS 21:S37-S45.
16. Iacomi F, Vincenti D, Vairo F, Solmone M, Mariano A, Piselli P, Puro V, Capobianchi MR, Antonucci G. 2009. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B. J Med Virol 81:1151-1156.
17. Lacombe K, Gozlan J, Boyd A, Bonnard P, Molina J-M, Miailhes P, Lascoux-Combe C, Zoulim F, Pacanowski J, Girard P-M. 2009. HBV blippers and rebounders under treatment with tenofovir in HIV/HBV co-infection. Conference on Retrovirus and Opportunistic Infection (San Francisco). Abstract 100.
18. Lada O, Gervais A, Branger M. 2008. De novo combination therapy of tenofovir disoproxil fumarate (TDF) plus lamivudine (LAM) or TDF plus emtricitabine (FTC) is associated with early virologic response in HIV/HBV co-infected patients. 59th Annual Meeting of the American Association for the Study of Liver Diseases (San Francisco). Abstract 922.
19. Lobato C, Tavares-Neto J, Rios-Leite M, Trepo C, Vitvitski L, Parvaz P, Zoulim F, D'Oliveira A, Jr., Paraná R. 2006. Intrafamilial prevalence of hepatitis B virus in Western Brazilian Amazon region: Epidemiologic and biomolecular study. J Gastroenterol Hepatol 21:863-868.
20. Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, Cooper DA, Lewin S, Dore GJ, Thio CL. 2006. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 20:863-870.
21. Matthews GV, Seaberg E, Dore GJ, Bowden S, Lewin SR, Sasadeusz J, Marks P, Goodman Z, Philp FH, Tang Y, Locarnini S, Thio CL. 2009. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS 23:1707-1715.
22. Mello FC, Souto FJ, Nabuco LC, Villela-Nogueira CA, Coelho HS, Franz HC, Saraiva JC, Virgolino HA, Motta-Castro AR, Melo MM, Martins RM, Gomes SA. 2007. Hepatitis B virus genotypes circulating in Brazil: Molecular characterization of genotype F isolates. BMC Microbiol 7:103.
23. Mendes-Corrêa MC, Barone AA, Cavalheiro N, Tengan FM, Guastini C. 2000. Prevalence of hepatitis B and C in the sera of patients with HIV infection in São Paulo, Brazil. Rev Inst Med Trop São Paulo 42:81-85.
24. Monteiro MR, do Nascimento MM, Passos AD, Figueiredo JF. 2004. Seroepidemiological survey of hepatitis B virus among HIV/AIDS patients in Belém. Pará-Brasil. Rev Soc Bras Med Trop 37:27-32.
25. Núñez M, Ramos B, Díaz-Pollán B, Camino N, Martín-Carbonero L, Barreiro P, González-Lahoz J, Soriano V. 2006. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Hum Retroviruses 22:842-848.
26. Oliveira LH, Silva IR, Xavier BL, Cavalcanti SM. 2001. Hepatitis B infection among patients attending a sexually transmitted diseases clinic in Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz 96:635-640.
27. Poustchi H, Mohamadkhani A, Bowden S, Montazeri G, Ayres A, Revill P, Farrell GC, Locarnini S, George J, Malekzadeh R. 2008. Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease. J Viral Hepat 15:753-760.
28. Santos EA, Sucupira MVF, Arabe J, Gomes SA. 2004. Hepatitis B virus variants in a HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine. BMC Infect Dis 4:29.
29. Sheldon J, Ramos B, Garcia-Samaniego J, Rios P, Bartholomeusz A, Romero M, Locarnini S, Zoulim F, Soriano V. 2007. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr 46:279-282.
30. Sitnik R, Pinho JR, Bertolini DA, Bernardini AP, Da Silva LC, Carrilho FJ. 2004. Hepatitis B virus genotypes and precore and core mutants in Brazilian patients. J Clin Microbiol 42:2455-2460.
31. Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, Mauss S, Rockstroh J. 2008. Care of HIV patients with chronic hepatitis B: Updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 22:1399-1410.
32. Souza MG, Passos AD, Machado AA, Figueiredo JF, Esmeraldino LE. 2004. HIV and hepatitis B vírus co-infection: Prevalence and risk factors. Rev Soc Bras Med Trop 37:391-395.
33. Takahashi K, Aoyama K, Ohno N, Iwata K, Akahane Y, Baba K, Yoshizawa H, Mishiro S. 1995. The pre core/core promoter mutant (T1762A1764) of hepatitis B virus: Clinical significance and easy method for detection. J Gen Virol 76:3159-3164.
34. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24:1596-1599.
35. Torresi J. 2002. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 25:97-106.
36. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, Fyfe J, Sozzi T, Jackson DC. 2002. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293:305-313.
37. Tovo CV, Dos Santos DE, de Mattos AZ, de Almeida PR, de Mattos AA, Santos BR. 2006. Ambulatorial prevalence of hepatitis B and C markers in patients with human immunodeficiency virus infection in a general hospital. Arq Gastroenterol 43:73-76.
38. Tuma P, Bottecchia M, Sheldon J, Soriano V. 2008. Prior lamivudine (LAM) failuremaydelay time to complete HBV-DNA suppression in HIV patients treated with tenofovir plus LAM. 59th Annual Meeting of the American Association for the Study of Liver Diseases (San Francisco). Abstract 967.
39. Wolters LM, Niesters HG, Hansen BE, van der Ende ME, Kroon FP, Richter C, Brinkman K, Meenhorst PL, de Man RA. 2002. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol 24:173-181.
40. Zago AM, Machado TF, Cazarim FL, Miranda AE. 2007. Prevalence and risk factors for chronic hepatitis B in HIV patients attended at a sexually-transmitted disease clinic in Vitoria, Brazil. Braz J Infect Dis 11:475-478.